Press releases

Bukwang Pharmaceutical announces that the company’s application to conduct phase 2 clinical study for new CNS drug candidate ‘JM-010’ has recently been approved by French authority. The study is planned to include major European countries, including Germany, France, and Spain, with approvals from other countries are also expected to be completed within this month with […]

to be completed within 2 years Bukwang Pharmaceutical (“Bukwang”) announced today that the phase 2 clinical study of JM-010, a new potential treatment for dyskinesia in Parkinson’s disease, has recently been initiated. JM-010 is currently developed by Copenhagen-based Contera Pharma, a subsidiary of Bukwang. About 90% of patients who have been taking L-dopa for 10 […]

3 million dollars invested by Medici Investment European Clinical phase 2 study of JM-010 to treat dyskinesia in Parkinson’s disease has been started Contera Pharma ApS (“Contera”), a subsidiary of Bukwang Pharmaceutical, has booked 3 billion KRW series A financing from Medici Investment. The proceeds from the financing will go to speed up the European […]

Bukwang Pharmaceutical Co., Ltd. (Bukwang) announced that JM-010 has been administered to the first patient in phase 2 study in Europe. In late 2019, Bukwang successfully initiated phase 2 clinical study of JM-010, which is being developed to treat dyskinesia in Parkinson’s disease, in a number of European countries, and the progress is cruising as […]

Contera Pharma is preparing for public offering in KOSDAQ Bukwang has recently received the investigational new drug (IND) clearance from the US Food and Drug Administration (FDA) to proceed with phase 2 clinical study of JM-010. JM-010, originating from a Danish bioventure company Contera Pharma, is currently under development for treating dyskinesia which emerges in […]

To strengthen its activities Contera Pharma has today opened an office in Seoul, Korea. The Seoul office will be headed by Minchang Kwon, Managing Director and Jai Hong Kwon, CFO. John Bondo Hansen, CEO says: Our new Seoul office will be a valuable addition to the Contera organization. I warmly welcome Minchang Kwon and Jai […]